Can Integrated Care Lead to Better Outcomes?

Shikha Mittoo, MD, MHS, FRCPC, is the medical director and co-founder of Involved Medicine, medical advisor for InfuseRX, a staff rheumatologist at University Health Network and an adjunct assistant professor at the University of Toronto, Canada. Dr. Mittoo is a rheumatologist with an interest in inflammatory arthritis and lung disease.

References

1. Brinkman GH, Norvang V, Noril ES, et al. Treat to target strategy in early rheumatoid arthritis versus routine care—A comparative clinical practice study. Semin Arthritis Rheum. 2018 Jul 25. pii: S0049-0172(18)30184-7.
2. Vermeet M, Kuper HH, Bernelot Moens HJ, et al. Adherence to treat-to-target strategy in early rheumatoid arthritis: Results of the DREAM remission induction cohort. Arthritis Res Ther. 2012 Nov 23;14(6):R254.
3. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum. 2005 Nov;52(11):3381–3390.
4. Primdahl J, Sørensen J, Horn HC, et al. Shared care or nursing consultations as an alternative to rheumatologist follow-up for rheumatoid arthritis outpatients with low disease activity—patient outcomes from a 2-year, randomised controlled trial. Ann Rheum Dis. 2014 Feb; 73(2):357–364.
5. Chung YL, Alexanderson H, Pipitone N, et al. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007 May 15;57(4):694–702.
6. Fogarty FA, Booth RJ, Gamble GD, et al. The effect of mindfulness-based stress reduction on disease activity in people with rheumatoid arthritis: A randomized controlled trial. Ann Rheum Dis. 2015 Feb;74(2):472–474.
7. Szczurko O, Cooley K, Millis EJ, et al. Naturopathic treatment of rotator cuff tendinitis among Canadian postal workers: A randomized controlled trial. Arthritis Rheum. 2009 Aug 15;61(8):1037–1045.
8. Häuser W, Bernardy K, Arnold B, et al. Efficacy of multicomponent treatment in fibromyalgia syndrome: A meta-analysis of randomized controlled clinical trials. Arthritis Rheum. 2009 Feb 15;61(2):216–224.
9. O’Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013 Jul 25;369(4):307–318.
10. Sephton SE, Salmon P, Weissbecker I, et al. Mindfulness meditation alleviates depressive symptoms in women with fibromyalgia: Results of a randomized clinical trial. Arthritis Rheum. 2007 Feb 15;57(1):77–85.
11. Fayad F, Ziade NR, Merheb G, et al. Patient preferences for rheumatoid arthritis treatments: Results from the national cross-sectional LERACS study. Patient Prefer Adherence. 2018 Aug 31;12:1619–1625. eCollection 2018.
12. Toupin-April K, Barton J, Fraenkel L, et al. Toward the development of a core set of outcome domains to assess shared decision-making interventions in rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting. J Rheumatol. 2017 Oct;44(10):1544–1550.
13. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study. Ann Rheum Dis. 2013 Oct;72(10):1605–1612.
14. Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): A 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017 Jun 10;389(10086);2304–2316.
15. Hazlewood GS, Bombardier C, Tomlinson G, et al. Treatment preferences of patients with early rheumatoid arthritis: A discrete-choice experiment. Rheumatology (Oxford). 2016 Nov;55(11)1959–1968.
16. Widdifield J, Paterson JM, Bernatsky S, et al. Access to rheumatologists among patients with newly diagnosed rheumatoid arthritis in a Canadian universal public healthcare system. BMJ Open. 2014 Jan 31;4(1):e003888.
17. Widdifield J, Paterson JM, Bernatsky S, et al. The rising burden of rheumatoid arthritis surpasses rheumatology supply in Ontario. Can J Public Health. 2013 Oct 31;104(7):e450–e455.
18. Arthritis Alliance of Canada.
19. Health fact sheets: Chronic conditions, 2015. Arthritis. Symbol of Statistics Canada.
20. Curran M. Integrated care is a fundamental design feature that will strengthen healthcare around the world. International Foundation for Integrated Care. 2017 May 25.
21. Service delivery and safety: WHO global strategy on people-centred and integrated health services. Interim report. World Health Organization. 2015.
22. Service delivery and safety: Framework on integrated people-centred health services. World Health Organization. 2016 May.
23. MacInnes J, Williams L. A review of integrated heart failure care. Prim Health Care Res Dev. 2018 Jun;1–8.
24. Koolen EH, van der Wees PJ, Westert GP, et al. The COPDnet integrated care model. Int J Chron Obstruct Pulmon Dis. 2018 Jul 19;13:2225–2235.
25. Sterling S, Chi F, Weisner C, et al. Association of behavioral health factors and social determinants of health with high and persistently high healthcare costs. Prev Med Rep. 2018 Jun 27;11:154–159.
26. Baxter S, Johnson M, Chambers D, et al. Understanding new models of integrated care in developed countries: A systematic review. NIHR Journals Library. 2018 Aug.
27. Central LHIN (Local Health Integration Network).
28. Guyatt GH, Haynes RB, Jaeschke RZ, et al. Users’ guides to the medical literature. JAMA. 2000;284(10):1290–1296.